306 pharmaceutical companies posted 2020 transcripts!

48　4，2020。，A306，，114，83，109。、、、、930。，77，65，400025；、25。，、、40。

 

A2020

 

A2020

 

A2020

 

、、……930

 

，、、、、930。

 

 

327.
4，10.
38%

 

55.
16，31.
85%

 

，，、，、、，、，IP，，。，，；，；“”，，。“”，、，、 、，，，。、，，，，， ；，，，。

 

，2016-2019，。2020、、、，，“，”，、、、，、，。

 

 

　　303.
1，6.
02%

 

　　36.
63，10.
27%

 

　　，，，、、，、、、、，。，（）、（）、（），。，、、，、、，。

 

　　It is worth mentioning that Fosun Pharma will have 39 single preparations or series in the pharmaceutical sector with sales exceeding 100 million yuan in 2020, a net increase of 3 compared to the same period last year.
For a long time, Fosun Pharma has taken innovative R&D as its core driving factor.
Through independent R&D, cooperative development, license introduction, and in-depth incubation, it focuses on tumor and immune regulation, four highs (hypertension, hyperlipidemia, hyperglycemia, hyperuricemia).
) And key disease areas such as complications and central nervous system to build and form technology platforms for small molecule innovative drugs, antibody drugs, and cell therapy, and actively explore cutting-edge technologies such as targeted protein degradation, RNA, and gene therapy to enhance innovation capabilities.
The total R&D investment in 2020 is 4.
003 billion yuan, a year-on-year increase of 15.
59%; of which, R&D expenses are 2.
795 billion yuan, a year-on-year increase of 36.
94%.
The R&D investment in the pharmaceutical sector was 3.
670 billion yuan, an increase of 17.
21% year-on-year; the R&D investment in the pharmaceutical business accounted for 16.
77% of the pharmaceutical business revenue; of which, R&D expenses were 2.
468 billion yuan, an increase of 727 million yuan year-on-year, an increase of 41.
76% year-on-year, accounting for the total revenue of the pharmaceutical business 11.
28%.

 

　　Xinhecheng

 

　　Revenue 10.
31 billion yuan, a year-on-year increase of 34.
64%

 

　　Net profit was 3.
564 billion yuan, a year-on-year increase of 64.
59%

 

　　As a leading vitamin company, Xinhecheng achieved a new record in 2020.
Xinhecheng said that performance growth is mainly due to strengthening the management of production and sales linkage, actively meeting customer needs, optimizing production plans, and actively coordinating transportation resources.
The market share of major products such as methionine has increased significantly, the market for vitamin C has been developed smoothly, and the production and sales of leaf alcohol series products have been further released.
Establish a “many-to-one” customer service model for R&D, production, application, and quality assurance to enhance customer stickiness and satisfaction, enrich the sales model, and increase sales of new products steadily.
In addition, adhere to the two-way force of independent research and development and open cooperation, promote the implementation of innovative results, take demand-oriented, focus on key technologies, and successfully build a molecular biology platform.
The company also adheres to the simultaneous advancement of business development and project construction, accelerates the pace of high-quality development, and always takes strategic goals as the guidance, promotes transformation and upgrading, and enhances core competitiveness.
Continuously improve the comprehensive competitiveness of old products by tapping the potential, improving quality and efficiency; continuously deploying new business and expanding the planned product library; of the 250,000 tons of methionine phase II project, the 100,000 tons of the plant was successfully commissioned and normal production, 150,000 tons The installation proceeded as planned, and the progress of the project was controllable; the biological fermentation project (Phase I) was officially put into operation, and other projects proceeded as planned.

 

　　77 net profits doubled! This is from nearly 40 million to over 2.
5 billion

 

　　As of now, 77 pharmaceutical companies have doubled their net profits.
Among them, Shengxiang Bio has soared 65 times a year, from nearly 40 million yuan to over 2.
5 billion yuan.
In addition, Ingram Medical and Daan Gene both increased by more than 25 times.

 

　　Shengxiang Bio

 

　　Revenue 4.
763 billion yuan, a year-on-year increase of 1203.
5%

 

　　Net profit was 2.
617 billion yuan, a year-on-year increase of 6527.
9%

 

　　Shengxiang Bio is an in vitro diagnostic total solution provider with independent innovative gene technology as the core, integrating the R&D, production, sales of diagnostic reagents and instruments, as well as third-party medical inspection services, with a net profit of nearly 40 million yuan in 2019 .
Regarding the significant increase in performance, Shengxiang Biotech stated that in the face of the global epidemic, the company actively responded, and built a full-scene new crown detection overall solution according to different anti-epidemic periods, different application scenarios, and different national conditions, and went all out to serve Epidemic prevention and control.
The products developed by the company have better met the market demand.
The sales performance of products and services such as COVID-19 nucleic acid detection reagents, nucleic acid detection instruments, related consumables, inspection services, etc.
has achieved major breakthroughs.
At the same time, the company's equipment sales and installed capacity growth further drive the company's entire line Incremental sales of reagents, a total of 6,122 instruments will be shipped in 2020, which is nearly 6 times the total shipment volume of the company since its establishment to 2019, accelerating the increase in the market share of the entire line of products.

 

　　Intech Medical

 

　　Revenue 13.
84 billion yuan, a year-on-year increase of 564.
29%

 

　　Net profit was 7.
007 billion yuan, a year-on-year increase of 3829.
6%

 

　　Ingram Medical's annual report shows that in 2020, the company's product export revenue increased by 436.
05% year-on-year, and its domestic product revenue increased by 2789.
72% year-on-year.
In terms of product categories, personal protection revenue was 13.
452 billion yuan, a year-on-year increase of 660.
23%, mainly due to the impact of domestic and foreign epidemic factors, the increase in the number of health inspections in medical institutions, and the increase in protection awareness of various industries and the public, which led to the sale of disposable gloves.
With substantial growth, product prices have also risen sharply; income from rehabilitation and nursing care is 215 million yuan, an increase of 5.
08% year-on-year; income from other products is 170 million yuan, an increase of 55.
78% year-on-year.
Ingram Medical said that due to the impact of the new crown epidemic in 2020, disposable gloves as a key anti-epidemic material will have a surge in global demand and short supply, which has brought huge development opportunities for the company.
The company's performance, industry status, market value development, and society Influencing and other aspects have achieved fruitful results, and for many years, we have focused on the improvement of disposable glove product quality, independent innovation of product lines, optimization of production technology, growth of sales team, continuous capacity building, etc.
, all of which have become The key factor for the rapid development of the company.

 

　　Source: Oriental Fortune.
com, Announcement of Listed Companies

　　The news of medicine net on April 8 stepped into April, and the 2020 annual report performance of listed companies ushered in a period of intensive disclosure.
At present, a total of 306 pharmaceutical companies in A-shares have disclosed their performance, of which 114 are official annual reports, 83 are performance bulletins, and 109 are performance forecasts.
The net profits of 9 companies including Yunnan Baiyao, Shanghai Pharmaceuticals, Fosun Pharma, Xinhecheng, and Changchun Hi-tech exceeded RMB 3 billion.
From the perspective of net profit growth, 77 companies doubled, Shengxiang Biotechnology soared 65 times a year, from nearly 40 million yuan to more than 2.
5 billion yuan; Ingram Medical and Daan Gene both increased by more than 25 times.
In addition, more than 40 companies including Sharp Aisi, Jincheng Pharmaceutical, and Zixin Pharmaceutical suffered losses.

 

2020 performance of 　　A- share pharmaceutical companies

 

　　A- share pharmaceutical companies' 2020 performance report

 

2020 performance forecast of 　　A- share pharmaceutical companies

 

　　Yunnan Baiyao, Fosun Pharma, Xinhecheng.
.
.
9 companies with net profit exceeding 3 billion

 

　　Among the pharmaceutical companies that have disclosed their performance, nine companies including Yunnan Baiyao, Shanghai Pharmaceuticals, Fosun Pharma, Xinhecheng, and Changchun High-tech have net profits of more than 3 billion yuan.

 

　　Yunnan Baiyao

 

　　Revenue 32.
74 billion yuan, a year-on-year increase of 10.
38%

 

　　Net profit was 5.
516 billion yuan, a year-on-year increase of 31.
85%

 

　　Regarding the rapid growth in performance, Yunnan Baiyao pointed out in its annual report that while focusing on the treatment and maintenance of traditional Chinese medicine and fully tapping the growth potential of existing products , the pharmaceutical sector actively expands new fields such as pharmaceutical materials science, medical equipment , and chronic disease management to make good use of the market.
Two core advantage platforms for planning and sales execution, internal integration of IP project support teams, external integration of domestic first-class planning teams to build a win-win sharing platform, and effective integration of market resources that meet the requirements of the industry chain.
While consolidating the foundation of toothpaste product brands, the health products segment also expands oral care products represented by mouthwash, and gradually completes the development from a strong brand of toothpaste to a strong brand of oral care; hygiene products are based on the completion of brand combing and adjustment , Accumulate small to achieve a full-scale ice-breaking; Beauty skin products are steadily growing while consolidating the brand positioning of "Provide consumers with customized skin problem solving and care solutions", and carry out double innovation and exploration of products and marketing models to support New growth in the future.
The TCM resources sector reshapes its business around "customer-centric", focuses and builds branded products, and strives to build a cloud medicine resource trading platform, a health regimen platform, a plant extract and API industry platform, through the standardization and model of the whole process Innovate, comprehensively reconstruct the value chain from upstream planting to downstream terminal product development and sales, and create a traditional Chinese medicine resource industry ecosystem.
Based on the regional market, the pharmaceutical business segment is deeply engaged in the pharmaceutical circulation business.
Based on information technology and intelligent facilities and equipment, it accelerates the transformation and development of a smart pharmaceutical supply chain service provider, efficiently speeds up hospital supply chain management operations, improves distribution efficiency, and improves supply chain coordination Ability; At the same time, increase the development of the new retail market, prepare for prescription circulation and graded diagnosis and treatment, and effectively undertake the share of hospital outflow prescriptions.

 

　　Yunnan Baiyao said that from 2016 to 2019, the company completed the mixed ownership reform in two steps, and further stimulated the development momentum of the company with institutional innovation .
In 2020, we will successively deploy in Beijing, Shanghai, Hong Kong, South Korea and other regions at home and abroad.
The journey of internationalization is steadily started.
In the future, under the guidance of the strategy of "Strengthening the Central and Breaking Through the Two Wings", we will continue to do a good job of medicines, health products, Chinese medicine resources, and provincial medicines.
At the same time, the four major business sectors are making efforts to expand the fields of medical aesthetics and orthopedics, and actively seek new breakthroughs on the track.

 

　　Fosun Pharma

 

　　Revenue 30.
31 billion yuan, an increase of 6.
02% year-on-year

 

　　Net profit was 3.
663 billion yuan, a year-on-year increase of 10.
27%

 

　　Fosun Pharma stated that on the one hand, the main driving factors for its performance are the launch of new products and the optimization of its product structure.
The group focuses on areas that are clinically demand-oriented, effective and in line with the development of modern medicine, through independent research and development, cooperative development, and licensing.
Diversified and multi-level cooperation modes such as, in-depth incubation, etc.
, promote the development and transformation of innovative technologies and products.
After more than ten years of continuous investment, in the past two years, Han Likang (rituximab injection), hantriyou (trastuzumab for injection), Su Kexin (avatropippa maleate), etc.
A number of varieties have been approved for listing and sold in large quantities, and innovative products have promoted sustainable growth in performance.
On the other hand, the integration effect is gradually emerging.
The group actively integrates R&D, supply chain, production and marketing systems to reduce costs, improve efficiency, enhance synergy, and promote performance growth.

 

　　It is worth mentioning that Fosun Pharma will have 39 single preparations or series in the pharmaceutical sector with sales exceeding 100 million yuan in 2020, a net increase of 3 compared to the same period last year.
For a long time, Fosun Pharma has taken innovative R&D as its core driving factor.
Through independent R&D, cooperative development, license introduction, and in-depth incubation, it focuses on tumor and immune regulation, four highs (hypertension, hyperlipidemia, hyperglycemia, hyperuricemia).
) And key disease areas such as complications and central nervous system to build and form technology platforms for small molecule innovative drugs, antibody drugs, and cell therapy, and actively explore cutting-edge technologies such as targeted protein degradation, RNA, and gene therapy to enhance innovation capabilities.
The total R&D investment in 2020 is 4.
003 billion yuan, a year-on-year increase of 15.
59%; of which, R&D expenses are 2.
795 billion yuan, a year-on-year increase of 36.
94%.
The R&D investment in the pharmaceutical sector was 3.
670 billion yuan, an increase of 17.
21% year-on-year; the R&D investment in the pharmaceutical business accounted for 16.
77% of the pharmaceutical business revenue; of which, R&D expenses were 2.
468 billion yuan, an increase of 727 million yuan year-on-year, an increase of 41.
76% year-on-year, accounting for the total revenue of the pharmaceutical business 11.
28%.

 

　　Xinhecheng

 

　　Revenue 10.
31 billion yuan, a year-on-year increase of 34.
64%

 

　　Net profit was 3.
564 billion yuan, a year-on-year increase of 64.
59%

 

　　As a leading vitamin company, Xinhecheng achieved a new record in 2020.
Xinhecheng said that performance growth is mainly due to strengthening the management of production and sales linkage, actively meeting customer needs, optimizing production plans, and actively coordinating transportation resources.
The market share of major products such as methionine has increased significantly, the market for vitamin C has been developed smoothly, and the production and sales of leaf alcohol series products have been further released.
Establish a “many-to-one” customer service model for R&D, production, application, and quality assurance to enhance customer stickiness and satisfaction, enrich the sales model, and increase sales of new products steadily.
In addition, adhere to the two-way force of independent research and development and open cooperation, promote the implementation of innovative results, take demand-oriented, focus on key technologies, and successfully build a molecular biology platform.
The company also adheres to the simultaneous advancement of business development and project construction, accelerates the pace of high-quality development, and always takes strategic goals as the guidance, promotes transformation and upgrading, and enhances core competitiveness.
Continuously improve the comprehensive competitiveness of old products by tapping the potential, improving quality and efficiency; continuously deploying new business and expanding the planned product library; of the 250,000 tons of methionine phase II project, the 100,000 tons of the plant was successfully commissioned and normal production, 150,000 tons The installation proceeded as planned, and the progress of the project was controllable; the biological fermentation project (Phase I) was officially put into operation, and other projects proceeded as planned.

 

　　77 net profits doubled! This is from nearly 40 million to over 2.
5 billion

 

　　As of now, 77 pharmaceutical companies have doubled their net profits.
Among them, Shengxiang Bio has soared 65 times a year, from nearly 40 million yuan to over 2.
5 billion yuan.
In addition, Ingram Medical and Daan Gene both increased by more than 25 times.

 

　　Shengxiang Bio

 

　　Revenue 4.
763 billion yuan, a year-on-year increase of 1203.
5%

 

　　Net profit was 2.
617 billion yuan, a year-on-year increase of 6527.
9%

 

　　Shengxiang Bio is an in vitro diagnostic total solution provider with independent innovative gene technology as the core, integrating the R&D, production, sales of diagnostic reagents and instruments, as well as third-party medical inspection services, with a net profit of nearly 40 million yuan in 2019 .
Regarding the significant increase in performance, Shengxiang Biotech stated that in the face of the global epidemic, the company actively responded, and built a full-scene new crown detection overall solution according to different anti-epidemic periods, different application scenarios, and different national conditions, and went all out to serve Epidemic prevention and control.
The products developed by the company have better met the market demand.
The sales performance of products and services such as COVID-19 nucleic acid detection reagents, nucleic acid detection instruments, related consumables, inspection services, etc.
has achieved major breakthroughs.
At the same time, the company's equipment sales and installed capacity growth further drive the company's entire line Incremental sales of reagents, a total of 6,122 instruments will be shipped in 2020, which is nearly 6 times the total shipment volume of the company since its establishment to 2019, accelerating the increase in the market share of the entire line of products.

 

　　Intech Medical

 

　　Revenue 13.
84 billion yuan, a year-on-year increase of 564.
29%

 

　　Net profit was 7.
007 billion yuan, a year-on-year increase of 3829.
6%

 

　　Ingram Medical's annual report shows that in 2020, the company's product export revenue increased by 436.
05% year-on-year, and its domestic product revenue increased by 2789.
72% year-on-year.
In terms of product categories, personal protection revenue was 13.
452 billion yuan, a year-on-year increase of 660.
23%, mainly due to the impact of domestic and foreign epidemic factors, the increase in the number of health inspections in medical institutions, and the increase in protection awareness of various industries and the public, which led to the sale of disposable gloves.
With substantial growth, product prices have also risen sharply; income from rehabilitation and nursing care is 215 million yuan, an increase of 5.
08% year-on-year; income from other products is 170 million yuan, an increase of 55.
78% year-on-year.
Ingram Medical said that due to the impact of the new crown epidemic in 2020, disposable gloves as a key anti-epidemic material will have a surge in global demand and short supply, which has brought huge development opportunities for the company.
The company's performance, industry status, market value development, and society Influencing and other aspects have achieved fruitful results, and for many years, we have focused on the improvement of disposable glove product quality, independent innovation of product lines, optimization of production technology, growth of sales team, continuous capacity building, etc.
, all of which have become The key factor for the rapid development of the company.

 

　　Source: Oriental Fortune.
com, Announcement of Listed Companies